Clinical Trial Update: Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating tusamitamab ravtansine in combination with ramucirumab for pretreated gastric or gastroesophageal cancer has been terminated, with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Cancer

Drugs mentioned

• Ramucirumab (ramucirumab)
• Tusamitamab ravtansine (SAR408701) (tusamitamab ravtansine)

Snippet

Sponsor: Sanofi | Conditions: Adenocarcinoma Gastric, Gastrooesophageal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-12-05